Trials / Completed
CompletedNCT02174432
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Trevi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nalbuphine HCl ER | nalbuphine HCl ER BID for up to 50 weeks |
Timeline
- Start date
- 2015-08-15
- Primary completion
- 2017-09-03
- Completion
- 2017-09-03
- First posted
- 2014-06-25
- Last updated
- 2025-05-21
- Results posted
- 2020-10-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02174432. Inclusion in this directory is not an endorsement.